培美曲塞治疗晚期胃肠道恶性肿瘤的临床疗效评价

目的 探讨培美曲塞治疗晚期胃肠道恶性肿瘤的临床疗效与安全性.方法 回顾性分析本院2010年1月至2012年11月人院的1 14例晚期胃肠道恶性肿瘤患者按是否给予培美曲塞治疗分为两组.单药化疗组均采用铂类、5-FU或紫杉类化疗药治疗,联合化疗组均在以上基础上加用培美曲塞治疗,比较两组患者各类型恶性肿瘤治疗效果、生存期与不良反应等.结果 联合化疗组治疗总有效率(RR)与疾病控制率(DCR)显著性高于单药化疗组,两组比较差异有统计学意义(P＜0.01);联合化疗组2年生存率明显高于单药化疗组(76.19％ vs.56.86％),差异有统计学意义(P＜0.05);3年生存率显著高于单药化疗组(49.21％ vs.23.53％),差异有统计学意义(P＜0.01);联合化疗组患者相关不良反应发生率明显高于单药化疗组(47.92％vs.69.84％),差异有统计学意义(P＜0.05).结论 培美曲塞治疗晚期胃肠道恶性肿瘤的临床疗效显著,但存在一定不良反应,应给予对症处理.

The clinical efficacy of pemetrexed in patients with advanced gastrointestinal cancer

Objective To discuss the clinical efficacy and safety ofpemetrexed in patients with advanced gastrointestinal cancer.Methods 114 patients with advanced gastrointestinal cancer admitted in our hospital from January 2010 to November 2012 were divided into two groups.Single-agent chemotherapy group was given platinum drugs,5-FU or taxane chemotherapy drug therapy,combined chemotherapy group was given pemetrexed on the basis.Compared the treatment effect of various types of cancer,survival time,and adverse reactions.Results The total effective rate (RR) and disease control rate (DCR) of combined chemotherapy group were significantly higher than those of single-agent chemotherapy group,with statistically significant differences (P＜0.01);2,3-year survival rate of combined chemotherapy group was significantly higher than that of singleagent chemotherapy group (76.19％ vs.56.86％,49.21％ vs.23.53％),with statistically significant differences (P＜0.05);the incidence of related adverse reactions of combined chemotherapy group was significantly lower than that of single-agent chemotherapy group (47.92％ vs.69.84％),with statistically significant difference (P＜0.05).Conclusion Clinical efficacy of pemetrexed in patients with advanced gastrointestinal cancer is significant,with some adverse reactions which should be given symptomatic treatment.